Jubilant Pharma

7 articles about Jubilant Pharma

• Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market

  11/6/2020

  Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil 200 mg in the U.S. market.

• Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership

  8/10/2020

  Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of understanding (“MOU”). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement (“ELDA”) for Navidea’s diagnostic imaging agent Tilmanocept (technetium Tc 99m tilmanocept injection)

• Jubilant Receives Favorable Rulings from the U.S. Patent Office Invalidating Bracco Rubidium-Infusion-System Patents

  2/17/2020

  YARDLEY, Pa., Feb. 17, 2020 (GLOBE NEWSWIRE) -- On February 7, 2020, Jubilant DraxImage Inc., and certain of its affiliates (“Jubilant”) were informed by the U.S. Patent Office that it agreed with Jubilant’s arguments that two rubidium-infusion-system patents owned by Bracco Diagnostics, Inc., (“Bracco”) are invalid.  Bracco had alleged that Jubilant’s RUBY-FILL ® Generator and RUBY Rubidium Elution System™ were infringing the two patents in a lawsuit filed in 2018, prompting Jubilant to ch

• Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®Used For the Diagnosis of Intra-Abdominal Infection and Inflammatory Bowel Disease

  1/27/2020

  Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada for Drax Exametazine® (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling).

• Jubilant Receives Favorable Ruling from the U.S. Courts for RUBY-FILL®

  12/11/2019

  On December 2, 2019, Jubilant DraxImage Inc. and certain of its affiliates received notice of the favorable decision of the U.S. International Trade Commission in its case against Bracco Diagnostics Inc.

• Jubilant Awarded Radiopharmaceutical Group Purchasing Agreement by Premier

  10/25/2019

  Jubilant Radiopharma announced today that its Radiopharmacies Division has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products.

• Jubilant Pharma To Raise Over $100 Million, Plans To Consolidate Pharma Biz

  6/2/2014